STAAR Surgical (NASDAQ:STAA) Shares Gap Down Following Analyst Downgrade

STAAR Surgical Company (NASDAQ:STAA)’s share price gapped down prior to trading on Thursday after Wedbush lowered their price target on the stock from $40.00 to $37.00. The stock had previously closed at $25.41, but opened at $24.08. Wedbush currently has an outperform rating on the stock. STAAR Surgical shares last traded at $24.3950, with a volume of 272,086 shares.

Several other equities research analysts have also recently weighed in on the stock. Zacks Research raised shares of STAAR Surgical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 4th. Mizuho boosted their price objective on shares of STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Stifel Nicolaus upped their price objective on shares of STAAR Surgical from $18.00 to $31.00 and gave the company a “hold” rating in a research note on Thursday, May 14th. Wall Street Zen lowered shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Finally, Wells Fargo & Company raised their target price on STAAR Surgical from $16.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, STAAR Surgical currently has a consensus rating of “Hold” and an average price target of $26.61.

STAAR Surgical News Summary

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: STAAR Surgical reported second-quarter 2026 revenue of approximately $93.5 million, substantially above analyst expectations near $90.6 million and more than double the prior-year period. Earnings also improved significantly from last year’s loss, with reports citing quarterly EPS of $0.16 to $0.31 versus a year-ago loss. STAAR Surgical Reports Second Quarter 2026 Results
• Positive Sentiment: Management expects to end 2026 with well over $200 million in cash, supporting investments in growth and leaving the company with a strong liquidity position. STAAR also plans to shift all China-related supply to Switzerland, which could improve supply-chain control and reduce geopolitical or regional production risks over time. STAAR Surgical Cash and Supply-Chain Update
• Neutral Sentiment: The earnings call highlighted procedure demand and geographic sales mix as important factors for the remainder of the year. Investors are assessing whether growth is broad-based and sustainable across markets. STAAR Surgical Q2 2026 Earnings Call Transcript
• Negative Sentiment: Some coverage reported EPS of $0.16, below the consensus estimate of $0.22, even though revenue exceeded expectations. This apparent earnings miss—and differing reported EPS figures across financial outlets—may be driving profit-taking and uncertainty after the release. STAAR Surgical Q2 Earnings Reaction

Institutional Investors Weigh In On STAAR Surgical

Institutional investors and hedge funds have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd increased its position in shares of STAAR Surgical by 2,605.1% during the third quarter. Caitong International Asset Management Co. Ltd now owns 1,055 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 1,016 shares during the period. Ascentis Independent Advisors bought a new position in STAAR Surgical in the first quarter worth about $77,000. Tower Research Capital LLC TRC lifted its holdings in STAAR Surgical by 375.0% in the second quarter. Tower Research Capital LLC TRC now owns 5,919 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 4,673 shares during the period. Russell Investments Group Ltd. lifted its holdings in STAAR Surgical by 9,928.9% in the third quarter. Russell Investments Group Ltd. now owns 4,513 shares of the medical instruments supplier’s stock worth $121,000 after buying an additional 4,468 shares during the period. Finally, Fifth Third Bancorp boosted its position in STAAR Surgical by 2,867.1% during the 1st quarter. Fifth Third Bancorp now owns 11,008 shares of the medical instruments supplier’s stock valued at $206,000 after acquiring an additional 10,637 shares in the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Stock Performance

The company has a 50-day simple moving average of $26.98 and a two-hundred day simple moving average of $24.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.31 and a current ratio of 5.12. The firm has a market capitalization of $1.23 billion, a P/E ratio of -57.48 and a beta of 1.26.

STAAR Surgical (NASDAQ:STAA) last announced its earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.05. The firm had revenue of $93.52 million during the quarter, compared to analyst estimates of $78.72 million. STAAR Surgical had a positive return on equity of 3.31% and a negative net margin of 7.24%.The business’s revenue was up 119.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.10) EPS. As a group, equities analysts forecast that STAAR Surgical Company will post 0.13 EPS for the current year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.